Daily News

Daily News

Senotherapy: a new horizon for COPD therapy

Clinical Trials Daily

2020 FEB 25 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- A new study on Health and Medicine - Chest Disease Research is now available. According to news reporting originating in London, United Kingdom, by NewsRx journalists, research stated, “There is increasing evidence that COPD is a disease of accelerated lung aging, with the accumulation of senescent cells, which lose their ability to repair and secrete multiple inflammatory proteins known as the senescence-associated secretory phenotype (SASP), which mimics the profile of inflammatory mediators secreted in COPD. This review discusses novel drugs (senotherapies) that target cellular senescence which may be a promising therapeutic approach to prevent currently unaddressed disease progression and mortality in COPD.”

The news reporters obtained a quote from the research from Imperial College London, “A major pathway leading to senescence is via the activation of PI3 kinase-mammalian target of rapamycin (mTOR) signaling. Existing drugs, such as rapamycin and metformin, target this pathway. Mitochondrial oxidative stress is a key driving mechanism for this pathway and mitochondria-targeted antioxidants are promising. A key finding in COPD is loss of anti-aging molecules such as sirtuin-1 and sirtuin-6, which are reduced by PI3K-mTOR signaling through microRNA-34a. Sirtuin activators are in development and inhibiting miR-34a restores sirtuin expression experimentally in COPD cells. Senolytic therapies induce apoptosis and removal of senescent cells and reduce the SASP response in animal models of aging and in pilot clinical studies of other age-related diseases. A combination of senolytics and drugs that inhibit cellular senescence (senostatics) may be a valuable new approach to COPD, especially if started in early disease.”

According to the news reporters, the research concluded: “Furthermore, COPD is associated with several comorbidities that share the same aging pathways, which may be spread by extracellular vesicles, so a single treatment for all these diseases is feasible in the future to extend healthspan.”

For more information on this research see: Senotherapy: a new horizon for COPD therapy. Chest, 2020;():. Chest can be contacted at: Amer Coll Chest Physicians, 3300 Dundee Road, Northbrook, IL 60062-2348, USA. (Elsevier - www.elsevier.com; Chest - http://www.journals.elsevier.com/chest-physician/)

Our news correspondents report that additional information may be obtained by contacting L.E. Donnelly, National Heart and Lung Institute, Imperial College London, London, UK. Additional authors for this research include J.R. Baker and P.J Barnes.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.chest.2020.01.027. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher of the journal Chest can be contacted at: Amer Coll Chest Physicians, 3300 Dundee Road, Northbrook, IL 60062-2348, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)